Orion Group Interim Report 1-6/2007
Operating profit at the same level as in the comparative period
EUR million |
Q2/07
|
Q2/06
Proforma |
Change
% |
Q1-Q2/07
|
Q1-Q2/06
Proforma |
Change
% |
2006
Proforma |
Net sales |
166.6 |
156.3 |
+6.6% |
345.8 |
329.8 |
+4.9% |
641.1 |
Operating profit (EBIT) |
44.3 |
42.9 |
+3.1% |
105.3 |
105.8 |
-0.5% |
196.7 |
% of net sales |
26.6% |
27.5% |
|
30.5% |
32.1% |
|
30.7% |
Profit before taxes |
44.3 |
42.6 |
+4.0% |
106.1 |
105.9 |
+0.2% |
197.3 |
% of net sales |
26.6% |
27.2% |
|
30.7% |
32.1% |
|
30.8% |
R&D expenses |
25.5 |
20.0 |
+27.1% |
47.1 |
41.1 |
+14.6% |
84.1 |
% of net sales |
15.3% |
12.8% |
|
13.6% |
12.5% |
|
13.1% |
Capital expenditure |
8.6 |
8.0 |
+7.1% |
14.7 |
12.2 |
+20.6% |
25.5 |
% of net sales |
5.2% |
5.1% |
|
4.2% |
3.7% |
|
4.0% |
Balance sheet total |
|
|
|
526.3 |
517.9 |
+1.6% |
588.1 |
Equity ratio, % |
|
|
|
72.2% |
72.8% |
|
75.4% |
Gearing, % |
|
|
|
-5.4% |
-5.1% |
|
-22.6% |
Interest-bearing
liabilities |
|
|
|
20.3 |
10.5 |
+93.5% |
9.8 |
Non-interest-bearing
liabilities |
|
|
|
126.1 |
130.6 |
-3.5% |
134.8 |
Cash and
cash equivalents |
|
|
|
40.6 |
29.8 |
+36.2% |
110.0 |
ROCE (before taxes),
% |
|
|
|
50.3% |
54.2% |
|
46.5% |
ROE (after taxes), % |
|
|
|
37.8% |
40.6% |
|
34.5% |
Earnings per share,
EUR |
0.23 |
0.23 |
+1.1% |
0.55 |
0.56 |
-1.8% |
1.03 |
Equity per share, EUR |
|
|
|
2.69 |
2.67 |
+0.8% |
3.14 |
Personnel
at the end of the period |
|
|
|
3 254 |
3 178 |
+2.4% |
3 061 |
EUR million |
Q2/07
|
Q2/06
Proforma |
Change
% |
Q1-
Q2/07 |
Q1-Q2/06
Proforma |
Change
% |
2006
Proforma |
Financial
period
Q3-Q4/06 | ||||
Net sales |
166.6 |
156.3 |
+6.6% |
345.8 |
329.8 |
+4.9% |
641.1 |
311.2 | ||||
Cost of goods sold |
-53.1 |
-50.2 |
+5.7% |
-107.1 |
-99.9 |
+7.2% |
-205.2 |
-105.2 | ||||
Gross profit |
113.5 |
106.0 |
+7.1% |
238.7 |
229.9 |
+3.9% |
435.8 |
205.9 | ||||
Other
operating income |
0.6 |
0.7 |
-8.9% |
1.3 |
2.2 |
-39.7% |
13.8 |
11.6 | ||||
Selling and marketing expenses |
-35.4 |
-33.3 |
+6.3% |
-69.0 |
-65.7 |
+5.1% |
-128.9 |
-63.2 | ||||
R&D expenses |
-25.5 |
-20.0 |
+27.1% |
-47.1 |
-41.1 |
+14.6% |
-84.1 |
-43.1 | ||||
Administrative
expenses |
-9.1 |
-10.5 |
-13.4% |
-18.7 |
-19.5 |
-4.3% |
-39.9 |
-20.4 | ||||
Operating profit |
44.3 |
42.9 |
+3.1% |
105.3 |
105.8 |
-0.5% |
196.7 |
90.9 | ||||
Financial income |
0.6 |
0.5 |
+20.1% |
1.9 |
1.8 |
+8.5% |
3.5 |
1.8 | ||||
Financial
expenses |
-0.6 |
-0.9 |
-30.4% |
-1.1 |
-1.7 |
-34.1% |
-3.0 |
-1.2 | ||||
Profit before taxes |
44.3 |
42.6 |
+4.0% |
106.1 |
105.9 |
+0.2% |
197.3 |
91.4 | ||||
Income tax expense |
-11.9 |
-10.7 |
+11.2% |
-28.2 |
-27.4 |
+3.2% |
-52.2 |
-24.8 | ||||
Profit
for the period |
32.3 |
31.8 |
+1.6% |
77.9 |
78.5 |
-0.8% |
145.1 |
66.6 | ||||
of which attributable to: | ||||||||||||
Parent company
shareholders |
32.3 |
31.8 |
+1.6% |
77.9 |
78.5 |
-0.8% |
145.1 |
66.6 | ||||
Minority interest |
0.0 |
0.0 |
|
0.0 |
0.0 |
|
0.0 |
0.0 | ||||
Earnings
per share, EUR* |
0.23 |
0.23 |
+1.1% |
0.55 |
0.56 |
-1.8% |
1.03 |
0.47 | ||||
Depreciation
and amortisation |
7.7 |
8.7 |
-12.2% |
16.2 |
17.5 |
-7.6% |
34.7 |
17.2 | ||||
Personnel
expenses |
40.0 |
37.7 |
+6.0% |
76.1 |
72.4 |
+5.0% |
145.8 |
73.3 |
EUR million |
6/07 |
6/06
Proforma |
Change
% |
12/06 |
Non-current assets: | ||||
Property, plant and equipment |
185.3 |
191.2 |
-3.1% |
187.1 |
Goodwill |
13.5 |
13.5 |
- |
13.5 |
Other intangible assets |
21.7 |
23.7 |
-8.2% |
21.9 |
Investments in associates |
0.1 |
0.1 |
- |
0.1 |
Available-for-sale investments |
1.0 |
1.0 |
-3.5% |
1.0 |
Pension asset |
55.2 |
49.2 |
+12.3% |
52.7 |
Deferred tax assets |
1.3 |
1.7 |
-23.9% |
1.4 |
Other non-current assets |
2.3 |
4.3 |
-46.1% |
3.8 |
Non-current assets total |
280.4 |
284.6 |
-1.5% |
281.4 |
Current assets: | ||||
Inventories |
107.4 |
110.4 |
-2.7% |
107.2 |
Trade receivables |
84.6 |
75.4 |
+12.2% |
75.0 |
Other receivables |
13.3 |
17.7 |
-25.1% |
14.4 |
Cash and cash equivalents |
40.6 |
29.8 |
+36.2% |
110.0 |
Current assets total |
245.9 |
233.3 |
+5.4% |
306.6 |
Assets total |
526.3 |
517.9 |
+1.6% |
588.1 |
EUR million |
6/07 |
6/06
Proforma |
Change
% |
12/06 |
Equity: | ||||
Share capital |
92.2 |
92.2 |
- |
92.2 |
Share issue |
17.8 |
17.8 |
- |
17.8 |
Share premium |
23.0 |
23.0 |
- |
23.0 |
Expendable fund |
0.4 |
0.5 |
-4.2% |
0.5 |
Retained earnings |
246.4 |
243.2 |
+1.3% |
309.9 |
Equity of the parent company shareholders |
379.9 |
376.8 |
+0.8% |
443.5 |
Minority interest |
0.0 |
0.0 |
- |
0.0 |
Equity total |
379.9 |
376.8 |
+0.8% |
443.5 |
Non-current liabilities: | ||||
Deferred tax liabilities |
49.9 |
53.2 |
-6.2% |
51.5 |
Pension liability |
1.0 |
0.8 |
+18.5% |
0.9 |
Provisions |
0.2 |
1.4 |
-83.4% |
0.6 |
Interest-bearing non-current liabilities |
7.5 |
7.9 |
-6.1% |
7.5 |
Other non-current liabilities |
0.2 |
1.4 |
-87.2% |
1.8 |
Non-current liabilities total |
58.8 |
64.8 |
-9.3% |
62.3 |
Current liabilities: | ||||
Trade payables |
26.5 |
21.9 |
+21.0% |
29.2 |
Other current liabilities |
48.1 |
51.5 |
-6.7% |
49.9 |
Provisions |
0.2 |
0.3 |
-46.3% |
0.9 |
Interest-bearing current liabilities |
12.8 |
2.5 |
+403.7% |
2.3 |
Current liabilities total |
87.6 |
76.3 |
+14.8% |
82.3 |
Equity and liabilities total |
526.3 |
517.9 |
+1.6% |
588.1 |
EUR million |
Share
capital |
Share
pre-
mium |
Expend-
able
funds |
Other
reser-
ves |
Change
in
trans-
lation
differ-
ences |
Retained
earn-
ings |
Equity
of the
parent
company
share-
holders |
Minor-
ity
interest |
In
total |
Equity on
1 Jul 06 |
92.2 |
17.8 |
23.0 |
0.5 |
-3.5 |
246.8 |
376.8 |
0.0 |
376.8 |
Change in
translation
differences |
|
|
|
|
0.1 |
|
0.1 |
|
0.1 |
Profit
for the period |
|
|
|
|
|
66.6 |
66.6 |
-0.0 |
66.6 |
Recognised
income
and
expenses
in total |
|
|
|
|
0.1 |
66.6 |
66.7 |
-0.0 |
66.7 |
Other changes |
|
|
|
-0.0 |
|
|
-0.0 |
|
-0.0 |
Equity on
1 Jan 07 |
92.2 |
17.8 |
23.0 |
0.5 |
-3.4 |
313.3 |
443.5 |
0.0 |
443.5 |
Change in
translation
differences |
|
|
|
|
-0.1 |
|
-0.1 |
|
-0.1 |
Profit
for the period |
|
|
|
|
|
77.9 |
77.9 |
0.0 |
77.9 |
Recognised
income
and
expenses
in total |
|
|
|
|
-0.1 |
77.9 |
77.7 |
0.0 |
77.7 |
Dividend |
|
|
|
|
|
-141.3 |
-141.3 |
|
-141.3 |
Other changes |
|
|
|
-0.0 |
|
-0.0 |
-0.0 |
-0.0 |
-0.0 |
Equity on
30 Jun 07 |
92.2 |
17.8 |
23.0 |
0.4 |
-3.5 |
249.9 |
379.9 |
0.0 |
379.9 |
EUR million |
Q1-Q2/07
|
Q1-Q2/06
Proforma |
2006
Proforma |
Financial
period
Q3-Q4/06 |
Cash flow from operating activities: | ||||
Operating profit |
105.3 |
105.8 |
196.7 |
90.9 |
Adjustments | ||||
Depreciation and amortisation |
16.2 |
17.5 |
34.7 |
17.2 |
Sales gains and losses and disposals of property, plant and equipment |
0.0 |
0.1 |
-9.8 |
-9.8 |
Unrealised foreign exchange gains and losses |
-0.4 |
-1.1 |
-0.4 |
0.7 |
Change in pension asset and pension obligation |
-2.4 |
-2.8 |
-6.3 |
-3.5 |
Change in provisions |
-1.1 |
-0.9 |
-1.2 |
-0.2 |
Other adjustments |
0.0 |
-1.1 |
-1.1 |
0.0 |
|
12.2 |
11.7 |
16.0 |
4.3 |
Change in working capital: | ||||
Change in non-interest-bearing current receivables |
-9.1 |
-6.8 |
-2.4 |
4.4 |
Change in inventories |
-0.2 |
-10.6 |
-7.5 |
3.2 |
Change in non-interest-bearing current liabilities |
-5.6 |
-23.7 |
-8.7 |
14.9 |
|
-14.8 |
-41.2 |
-18.6 |
22.5 |
Interest paid |
-0.9 |
-2.2 |
-3.8 |
-1.5 |
Interest received |
2.0 |
1.8 |
3.5 |
1.7 |
Income taxes paid |
-28.2 |
-16.2 |
-52.5 |
-36.3 |
Net cash from operating activities |
75.6 |
59.8 |
141.4 |
81.6 |
Cash flow from investing activities: | ||||
Purchases of property, plant, equipment
and intangible assets |
-13.9 |
-10.5 |
-22.8 |
-12.3 |
Acquisition of subsidiary, net of cash |
- |
-1.2 |
-1.2 |
- |
Proceeds from sale of property, plant, equipment,
intangible assets and available-for-sale investments |
0.5 |
0.7 |
13.0 |
12.3 |
Net cash used in investing activities |
-13.5 |
-11.0 |
-10.9 |
0.0 |
Cash flow from financing activities: | ||||
Share issue and share capital increase
based on the use of stock options |
- |
21.4 |
21.4 |
- |
Change in short-term loans |
10.0 |
-46.5 |
-47.5 |
-1.0 |
Repayments of long-term loans |
-0.4 |
-0.2 |
-0.6 |
-0.4 |
Dividends paid |
-141.4 |
-118.2 |
-118.2 |
0.0 |
Net cash used in financing activities |
-131.8 |
-143.5 |
-144.9 |
-1.4 |
Net change in cash and cash equivalents |
-69.6 |
-94.6 |
-14.4 |
80.2 |
Cash and cash equivalents
at the beginning of the period |
110.0 |
124.5 |
124.5 |
29.8 |
Foreign exchange adjustments |
0.2 |
0.0 |
-0.1 |
0.0 |
Net change in cash and cash equivalents |
-69.6 |
-94.6 |
-14.4 |
80.2 |
Cash and cash equivalents at the end of the period |
40.6 |
29.8 |
110.0 |
110.0 |
EUR million |
Q1-Q2/07
|
Q1-Q2/06
Proforma |
2006
Proforma |
Financial
period
Q3-Q4/06 |
Carrying amount at the beginning of the period |
187.1 |
196.4 |
196.4 |
191.2 |
Additions |
11.3 |
8.4 |
19.0 |
10.5 |
Disposals |
-0.6 |
-0.7 |
-2.7 |
-1.9 |
Depreciation |
-12.5 |
-12.9 |
-25.6 |
-12.7 |
Carrying amount at the end of the period |
185.3 |
191.2 |
187.1 |
187.1 |
EUR million |
6/07 |
6/06
Proforma |
12/06 |
Contingent for own liabilities: | |||
Mortgages on land and buildings |
25.5 |
27.9 |
25.5 |
of which those to the Orion Pension Fund |
9.0 |
11.4 |
9.0 |
Guarantees |
1.5 |
1.9 |
1.8 |
Contingent for liabilities of other parties: | |||
Mortgages on land and buildings |
- |
9.5 |
- |
Guarantees |
- |
7.1 |
- |
Other liabilities: | |||
Leasing liabilities (excl. finance leasing contracts) |
4.7 |
3.8 |
5.2 |
Other liabilities |
0.3 |
0.3 |
0.3 |
EUR million |
6/07 |
6/06
Proforma |
12/06 |
Currency forward contracts: | |||
- fair value |
0.5 |
0.7 |
0.3 |
- nominal value |
74.4 |
75.6 |
58.5 |
EUR million |
Q1-Q2/07
|
Q1-Q2/06
Proforma |
2006
Proforma |
Financial
period
Q3-Q4/06 |
Management benefits |
1.8 |
1.2 |
2.1 |
1.0 |
Non-current liabilities to the pension fund
at the end of the period |
6.0 |
6.0 |
6.0 |
6.0 |
EUR million |
Q2/07
|
Q2/06
Proforma |
Change
% |
Q1-Q2/07 |
Q1-Q2/06
Proforma |
Change
% |
2006
Proforma |
Financial
period
Q3-Q4/06 |
Pharmaceuticals |
156.8 |
146.4 |
+7.1% |
324.7 |
309.2 |
+5.0% |
601.4 |
292.0 |
Diagnostics |
10.3 |
10.4 |
-1.0% |
22.1 |
21.6 |
+2.1% |
41.5 |
19.9 |
Group items |
-0.5 |
-0.5 |
-11.9% |
-1.0 |
-1.1 |
-8.0% |
-1.8 |
-0.7 |
Group total |
166.6 |
156.3 |
+6.6% |
345.8 |
329.8 |
+4.9% |
641.1 |
311.2 |
EUR million |
Q2/07
|
Q2/06
Proforma |
Change
% |
Q1-Q2/07 |
Q1-Q2/06
Proforma |
Change
% |
2006
Proforma |
Financial
period
Q3-Q4/06 |
Pharmaceuticals |
45.6 |
43.3 |
+5.2% |
106.3 |
105.3 |
+0.9% |
189.9 |
84.6 |
Diagnostics |
1.8 |
1.7 |
+10.1% |
5.1 |
4.5 |
+13.0% |
6.6 |
2.1 |
Group items |
-3.2 |
-2.1 |
+54.3% |
-6.0 |
-4.0 |
+50.6% |
0.2 |
4.2 |
Group total |
44.3 |
42.9 |
+3.1% |
105.3 |
105.8 |
-0.5% |
196.7 |
90.9 |
EUR million |
Q2/07 |
Q1/07 |
Q4/06 |
Q3/06 |
Q2/06
Proforma |
Q1/06
Proforma |
Pharmaceuticals |
156.8 |
167.9 |
152.1 |
139.9 |
146.4 |
162.9 |
Diagnostics |
10.3 |
11.8 |
10.4 |
9.5 |
10.4 |
11.2 |
Group items |
-0.5 |
-0.5 |
-0.4 |
-0.4 |
-0.5 |
-0.5 |
Group total |
166.6 |
179.2 |
162.2 |
149.0 |
156.3 |
173.5 |
EUR million |
Q2/07 |
Q1/07 |
Q4/06 |
Q3/06 |
Q2/06
Proforma |
Q1/06
Proforma |
Pharmaceuticals |
45.6 |
60.7 |
39.5 |
45.1 |
43.3 |
62.0 |
Diagnostics |
1.8 |
3.2 |
0.6 |
1.5 |
1.7 |
2.8 |
Group items |
-3.2 |
-2.9 |
-3.5 |
7.7 |
-2.1 |
-1.9 |
Group total |
44.3 |
61.1 |
36.6 |
54.3 |
42.9 |
62.9 |
EUR million |
Q2/07 |
Q1/07 |
Q4/06 |
Q3/06 |
Q2/06
Proforma |
Q1/06
Proforma |
Finland |
48.6 |
50.1 |
49.0 |
45.2 |
45.4 |
44.8 |
Scandinavia |
25.3 |
24.1 |
23.4 |
21.2 |
24.2 |
22.5 |
Other Europe |
57.5 |
63.7 |
58.4 |
52.8 |
52.7 |
69.6 |
North America |
20.1 |
24.1 |
22.0 |
20.1 |
20.5 |
20.4 |
Other markets |
15.1 |
17.1 |
9.4 |
9.7 |
13.4 |
16.2 |
Group total |
166.6 |
179.2 |
162.2 |
149.0 |
156.3 |
173.5 |
EUR million |
Q2/07
|
Q2/06
Proforma |
Change
% |
Q1-Q2/07 |
Q1-Q2/06
Proforma |
Change
% |
2006
Proforma |
Financial
period
Q3-Q4/06 |
Net sales |
156.8 |
146.4 |
+7.1% |
324.7 |
309.2 |
+5.0% |
601.4 |
292.0 |
Operating profit |
45.6 |
43.3 |
+5.2% |
106.3 |
105.3 |
+0.9% |
189.9 |
84.6 |
% of net sales |
29.1% |
29.6% |
|
32.7% |
34.1% |
|
31.6% |
29.0% |
Capital expenditure |
7.9 |
7.5 |
+4.7% |
13.5 |
11.3 |
+20.0% |
23.1 |
11.8 |
Net sales from
own proprietary products |
70.1 |
63.4 |
+10.6% |
147.0 |
143.9 |
+2.2% |
274.9 |
131.0 |
R&D expenses |
24.5 |
19.0 |
+29.2% |
45.2 |
39.1 |
+15.6% |
79.7 |
40.6 |
Personnel at the
end of the period |
|
|
|
2 926 |
2 846 |
+2.8% |
2 742 |
2 742 |
EUR million |
Q2/07
|
Q2/06
Proforma |
Change
% |
Q1-Q2/07 |
Q1-Q2/06
Proforma |
Change
% |
2006
Proforma |
Proprietary Products |
63.7 |
55.7 |
+14.3% |
135.0 |
132.7 |
+1.7% |
256.6 |
Specialty Products |
58.9 |
55.6 |
+5.9% |
120.6 |
110.8 |
+8.9% |
218.7 |
Animal Health |
18.6 |
16.7 |
+11.6% |
36.2 |
32.1 |
+12.6% |
63.3 |
Fermion |
9.7 |
9.9 |
-1.9% |
20.8 |
22.1 |
-6.1% |
38.5 |
Other
pharmaceutical business |
5.9 |
8.4 |
-30.4% |
12.1 |
11.5 |
+5.9% |
24.2 |
Group total |
156.8 |
146.4 |
+7.1% |
324.7 |
309.2 |
+5.0% |
601.4 |
EUR million |
Q2/07
|
Q2/06
Proforma |
Change
% |
Q1-Q2/07 |
Q1-Q2/06
Proforma |
Change
% |
2006
Proforma |
Stalevo (Parkinson's disease) |
28.6 |
23.1 |
+23.8% |
61.7 |
55.2 |
+11.7% |
111.3 |
Comtess/Comtan
(Parkinson's disease) |
18.8 |
17.6 |
+6.8% |
40.3 |
39.7 |
+1.6% |
74.7 |
Domitor, Domosedan and
Antisedan (animal sedatives) |
8.1 |
6.8 |
+19.0% |
16.0 |
13.7 |
+16.4% |
26.0 |
Calcimagon (osteoporosis) |
4.6 |
2.5 |
+79.4% |
7.9 |
6.1 |
+29.5% |
11.7 |
Burana (inflammatory pain) |
3.6 |
3.0 |
+22.8% |
7.7 |
5.2 |
+47.7% |
12.0 |
Easyhaler (asthma) |
3.9 |
4.0 |
-3.4% |
7.6 |
8.8 |
-13.2% |
15.9 |
Divina-series
(menopausal symptoms) |
3.7 |
4.1 |
-11.0% |
7.3 |
8.1 |
-9.6% |
16.2 |
Simdax (heart failure) |
3.1 |
3.4 |
-6.2% |
6.6 |
7.6 |
-12.8% |
13.2 |
Enanton (prostate cancer) |
3.2 |
3.3 |
-2.7% |
6.5 |
6.8 |
-3.3% |
13.3 |
Marevan (anticoagulant) |
2.3 |
2.0 |
+18.5% |
4.2 |
3.9 |
+9.0% |
7.0 |
In total |
79.9 |
69.8 |
+14.6% |
165.9 |
155.1 |
+7.0% |
301.2 |
Share of total
pharmaceutical net sales |
51% |
48% |
|
51% |
50% |
|
50% |
EUR million |
Q2/07
|
Q2/06
Proforma |
Change
% |
Q1-Q2/07
|
Q1-Q2/06
Proforma |
Change
% |
2006
Proforma |
Financial
period
Q3-Q4/06 |
Net sales |
10.3 |
10.4 |
-1.0% |
22.1 |
21.6 |
+2.1% |
41.5 |
19.9 |
Operating profit |
1.8 |
1.7 |
+10.1% |
5.1 |
4.5 |
+13.0% |
6.6 |
2.1 |
% of net sales |
17.7% |
15.9% |
|
23.0% |
20.8% |
|
15.9% |
10.6% |
Capital
expenditure |
0.3 |
0.4 |
-35.9% |
0.4 |
0.7 |
-40.2% |
1.4 |
0.8 |
Personnel
at the end of the period |
|
|
|
294 |
294 |
+0.2% |
289 |
289 |
|
Class |
A |
Class |
B |
A and B |
in total |
Share capital |
36.1 |
EUR million |
56.1 |
EUR million |
92.2 |
EUR million |
Total number of shares |
53 488 035 |
pcs |
87 769 793 |
pcs |
141 257 828 |
pcs |
Minimum share capital |
- |
|
- |
|
50 |
EUR million |
Maximum share capital |
- |
|
- |
|
2 000 |
EUR million |
Share of total share stock |
38 |
% |
62 |
% |
100 |
% |
Counter book value
of share |
0.65 |
EUR |
0.65 |
EUR |
- |
|
Votes per share |
20 |
votes |
1 |
vote |
|
|
Trading code on the
Helsinki Stock Exchange |
|
ORNAV |
|
ORNBV |
|
|
|
Class |
A |
Class |
B |
A and B |
in total |
Total number
of shares traded |
2 137 925 |
pcs |
56 178 149 |
pcs |
58 316 074 |
pcs |
Share of total share stock |
4.0 |
% |
64.5 |
% |
41.3 |
% |
Lowest quotation |
15.07 |
EUR |
15.96 |
EUR |
|
|
Highest quotation |
19.19 |
EUR |
19.19 |
EUR |
|
|
Closing quotation
on 2 January 2007 |
16.50 |
EUR |
16.50 |
EUR |
|
|
Closing quotation
on 30 June 2007 |
18.52 |
EUR |
18.54 |
EUR |
|
|
Market capitalisation
on 30 June 2007 |
990.6 |
EUR million |
1 627.3 |
EUR million |
2 617.9 |
EUR million |
|
Q2/07
|
Q2/06
Proforma |
Change
% |
Q1-Q2/07 |
Q1-Q2/06
Proforma |
Change
% |
2006
Proforma |
Financial
period
Q3-Q4/06 |
Earnings per share,
EUR |
0.23 |
0.23 |
+1.1% |
0.55 |
0.56 |
-1.8% |
1.03 |
0.47 |
Equity per share,
EUR |
|
|
|
2.69 |
2.67 |
+0.8% |
3.14 |
3.14 |
Average number of
shares, 1 000 pcs |
141 258 |
140 594 |
|
141 258 |
139 852 |
|
140 561 |
141 258 |
Return on capital employed (ROCE), %
|
= |
Profit before taxes + interest and other financial expenses |
x 100 | ||
Total assets - non-interest-bearing liabilities (annual average) | |||||
Return on equity (ROE), % |
= |
Profit for the period |
x 100 | ||
Equity of the parent company shareholders + minority interest (annual average)
| |||||
Equity ratio, % |
= |
Equity of the parent company shareholders + minority interest |
x 100 | ||
Total assets - advances received | |||||
Gearing, %
|
= |
Interest-bearing liabilities - Cash and cash equivalent |
x 100 | ||
Equity of the parent company shareholders + minority interest | |||||
Earning per share, EUR
|
= |
Profit available for the parent company shareholders |
| ||
Average number of shares
|
| ||||
Equity per share, EUR |
= |
Equity of the parent company shareholders |
| ||
Number of shares at the end of the period
|
| ||||
Market capitalisation, EUR million |
= |
Number of shares at the end of the period |
x |
Closing quotation of the period |
|